$6.19 Million is the total value of Copernicus Capital Management, LLC's 14 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $755,000 | -19.7% | 10,000 | -6.7% | 12.20% | -16.7% |
| REGN | New | REGENERON PHARMACEUTICALS | $710,000 | – | 1,500 | +100.0% | 11.47% | – |
| FATE | Buy | FATE THERAPEUTICS INC | $660,000 | +123.7% | 8,000 | +146.9% | 10.66% | +131.9% |
| ABBV | Buy | ABBVIE INC | $649,000 | +29.5% | 6,000 | +28.3% | 10.49% | +34.3% |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $645,000 | -11.5% | 3,000 | -2.8% | 10.42% | -8.3% |
| RVMD | New | REVOLUTION MEDICINES INC | $459,000 | – | 10,000 | +100.0% | 7.42% | – |
| RCKT | ROCKET PHARMACEUTICALS INC | $355,000 | -19.1% | 8,000 | 0.0% | 5.74% | -16.2% | |
| GRTS | New | GRITSTONE ONCOLOGY INC | $349,000 | – | 37,000 | +100.0% | 5.64% | – |
| TGTX | Buy | TG THERAPEUTICS INC | $337,000 | +10.9% | 7,000 | +19.7% | 5.44% | +14.9% |
| ARDX | New | ARDELYX INC | $331,000 | – | 50,000 | +100.0% | 5.35% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $281,000 | – | 10,000 | +100.0% | 4.54% | – |
| BCEL | New | ATRECA INC | $276,000 | – | 18,000 | +100.0% | 4.46% | – |
| TDOC | Sell | TELADOC HEALTH INC | $273,000 | -29.8% | 1,500 | -22.8% | 4.41% | -27.2% |
| ORTX | New | ORCHARD THERAPEUTICS PLCads | $109,000 | – | 15,000 | +100.0% | 1.76% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -12,091 | -100.0% | -3.48% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -2,000 | -100.0% | -4.05% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -3,740 | -100.0% | -4.47% | – |
| NBIX | Exit | NEUROCRINE BIOSCIENCES INC | $0 | – | -3,089 | -100.0% | -4.61% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -2,788 | -100.0% | -5.02% | – |
| IGMS | Exit | IGM BIOSCIENCES INC | $0 | – | -4,000 | -100.0% | -5.50% | – |
| IQV | Exit | IQVIA HLDGS INC | $0 | – | -2,094 | -100.0% | -5.84% | – |
| BMY | Exit | BRISTOL-MYERS SQUIBB CO | $0 | – | -11,327 | -100.0% | -10.96% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC | 15 | Q2 2021 | 28.6% |
| THERMO FISHER SCIENTIFIC INC | 10 | Q3 2021 | 13.8% |
| ZOETIS INC | 10 | Q1 2020 | 13.0% |
| FATE THERAPEUTICS INC | 9 | Q3 2021 | 13.7% |
| ILLUMINA INC | 9 | Q4 2019 | 11.8% |
| BIOMARIN PHARMACEUTICAL INC | 8 | Q3 2021 | 14.7% |
| BRISTOL-MYERS SQUIBB CO | 8 | Q4 2020 | 12.2% |
| INTUITIVE SURGICAL INC | 7 | Q2 2019 | 11.8% |
| STRYKER CORP | 7 | Q2 2019 | 11.6% |
| IQVIA HLDGS INC | 7 | Q4 2020 | 8.2% |
View Copernicus Capital Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-16 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-14 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-14 |
View Copernicus Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.